ADIL · Adial Pharmaceuticals
As of June 11, 2026, Adial Pharmaceuticals, Inc. was acquired by Azora Therapeutics, Inc. Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Market Cap
13.26M
52 Wk Range
$1.31 - $8.75
Previous Close
$3.71
Open
$3.83
Volume
83,085
Day Range
$3.82 - $5.15
Enterprise Value
-18.71M
Cash
28.71M
Avg Qtr Burn
-6.363M
Insider Ownership
7.08%
Institutional Own.
30.04%
Qtr Updated
Jun 30th 2026
